Inventiva(US:IVA) GlobeNewswire News Room·2024-10-21 12:30Core Viewpoint - Inventiva announced that the results of the Phase 2 LEGEND trial, evaluating lanifibranor in combination with empagliflozin for patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type-2 Diabetes (T2D), have been accepted for presentation at the 75th Annual AASLD The Liver Meeting® 2024 [1] Group 1: Company Overview - Inventiva is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for MASH/NASH and other diseases with significant unmet medical needs [3] - The company is advancing one clinical candidate, lanifibranor, which is currently in a pivotal Phase III clinical trial (NATiV3) for MASH/NASH treatment [3] - Inventiva has a pipeline that includes two preclinical programs and is exploring additional development opportunities [3] Group 2: Product Details - Lanifibranor is an orally-available small molecule that acts as a pan-PPAR agonist, targeting all three PPAR isoforms, which contributes to its favorable tolerability profile observed in clinical trials [2] - The FDA has granted Fast Track and Breakthrough Therapy designations to lanifibranor for MASH/NASH treatment [2] Group 3: Upcoming Presentation - The presentation titled "Combination therapy of lanifibranor with empagliflozin: metabolic improvement in patients with MASH and T2D" will take place on November 18, 2024, from 8:00 AM to 5:00 PM PST [2]